Consultative Services Offered

Alchimia Partners can provide strategic advice and consultation across a broad range of areas, including technology assessments, due diligence, review of business development opportunities, analysis of clinical data, strategic product development and development of investor materials, with a focus on therapeutics, both small molecule and biologics. Our clients have included biotechnology and pharmaceutical companies, venture capital and hedge funds, and law firms. Engagements can be structured as consultative projects or interim management positions.

  • Typical corporate engagements would include:
  • Product development strategic planning across preclinical, CMC, clinical and regulatory domains, including development of target product profile, product development plan, clinical trial design and protocol development.
  • Writing and review of INDs and other FDA correspondence and submissions.
  • In-depth review and analysis of competitive positioning of individual product candidates or entire portfolios, including due diligence on prospective in-licensing or acquisition candidates.
  • Building and reviewing financial models, including corporate financial statements, market models and budgets.
  • Preparation of due diligence materials for use in prospective partnering, out-licensing and asset sale discussions.
  • Creating investor materials such as slide presentations, executive summaries and business plans, and interacting with investors and potential investors at conferences, meetings and roadshows.
  • Scientific and medical writing, including composing manuscripts, and poster and slide presentations for medical or research meetings.
  • Defining inventive disclosures and drafting patent applications, in conjunction with in-house or outside patent counsel.
  • Serving as an expert witness in securities litigation in which the materiality of preclinical or clinical data, or disclosures relating to such data, to regulatory events including product approvals, or to sales or other financial forecasts, are at issue.

  • Investor engagements would include:
  • In-depth due diligence on companies or drugs, including (when appropriate) a detailed review of existing clinical data with an assessment of the likelihood of success at various future anticipated clinical and regulatory milestones.
  • Review of an existing investment portfolio with a goal of determining those investments with the best future prospects.
  • Support to portfolio company management teams, across the spectrum of activities defined above, on a consultative or interim executive basis.
  • Interim or permanent Board membership.